Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leysan M. Khasanova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Promising opportunities to improve polio vaccines

    by E. E. Evreinova, L. M. Khantimirova, V. A. Shevtsov, V. A. Merkulov, V. P. Bondarev

    Polioviruses belong to Enterovirus C species and cause severe lesions of the nervous system. In the post-polio eradication era, the World Health Organisation recommends inactivated polio vaccines for effective long-term protection of the population. In order to meet the needs of global health, it is planned to increase the use of traditional and optimised inactivated polio vaccines and introduce new types of vaccines that are being developed based on the current understanding of RNA-containing viruses. The aim of the study was to analyse ways of improving vaccine preparations and to review promising areas for polio immunoprophylaxis development. The authors considered innovations across all stages of the technological process, aimed at obtaining optimised vaccines, as well as vaccine delivery systems. The article presents information on new vaccine strains and cell lines for vaccine production. The authors summarised the results of clinical studies of inactivated vaccines, new vaccines based on genetically stable vaccine strains of poliovirus, and vaccines containing virus-like particles. The most likely candidates for introduction are the vaccines based on virus-like particles obtained from genetically modified strains of poliovirus. At the moment, many issues related to current trends in improving the immunoprophylaxis of poliomyelitis are debatable and need to be addressed in the near future.


  • Open Access

    Challenges in development and authorisation of gene therapy products

    by A. A. Soldatov, Zh. I. Avdeeva, D. V. Gorenkov, L. M. Khantimirova, S. G. Guseva, V. A. Merkulov

    There are a lot of diseases known today, which are caused by genetic abnormalities. Advances in genetics and biotechnology brought about gene editing technologies that can produce almost any gene, which ultimately led to the emergence of a new class of medicines - gene therapy products (GTPs). The aim of the study was to analyse international experience in development and authorisation of GTPs. The review highlights the challenges in GTP development, related to the search for an optimal approach to therapeutic gene delivery to the target cells. Viral vectors were shown to be a promising gene delivery system, with adenovirus (AV) and adeno-associated virus (AAV) based products demonstrating the highest efficacy and safety. The paper reviews current approaches to gene editing that allow modification of AVs and AAVs to improve GTP efficacy and safety. These modifications are carried out with the aim of, e.g., including a large therapeutic gene into a viral vector, decreasing viral protein expression levels, and decreasing viral vector immunogenicity. The review summarises GTP authorisation procedures in the USA and the European Union, including data on FDA and EMA subcommittees and departments entrusted with advisory functions. The paper mentions that there is one Russian-produced GTP authorised in the Russian Federation, and some other GTPs are in the pipeline. Therefore, the Russian regulatory framework and the Eurasian regulations and recommendations should be updated in order to accommodate for GTP development and authorisation.


  • The efficacy of medicinal products based on plasma immunoglobulins and monoclonal antibodies for the treatment and prevention of COVID-19

    by A.A. Soldatov, Zh.I. Avdeeva, D.V. Gorenkov, L.M. Khantimirova, Yu.S. Paramonova, E.M. Smolina, V.P. Bondarev, V.A. Merkulov

    Эффективность применения препаратов на основе иммуноглобулинов плазмы и моноклональных антител для лечения и профилактики COVID-19


  • Open Access

    Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines

    by L. M. Khantimirova, D. V. Gorenkov, S. G. Guseva, V. A. Merkulov, A. A. Soldatov

    At present, there are not much data on the clinical use of live recombinant viral vector vaccines. Characteristics of new vaccines should be factored into requirements/recommendations for quality control, preclinical and clinical studies of vaccines in order to enable further risk/benefit assessment. The aim of this study was to analyse current approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines. The paper provides an overview of the licensed live viral vector vaccines and those at various stages of clinical trials. The authors analysed Russian, European, American, and Japanese guidelines related to quality issues, preclinical and clinical studies of live viral vector vaccines. The analysis demonstrated that the regulatory requirements for live recombinant viral vector vaccines include assessment of a detailed rationale for vaccine development, including information on the choice of the vector, the origin of the heterologous antigen gene(s), elements related to the transgene(s) expression, as well as assessment of the genetic and phenotypic stability of the recombinant virus, the risk of reversion to virulence or recombination with wild type strains, the potential for virus genome integration into the host cell chromosome, the pre-existing immunity to the vector, the intensity of the immune response elicited by the vector, and the reusability of the vector. The choice and number of applicable toxicological and pharmacological models will depend on these aspects. The results of the analysis of approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines may be used in the development of Russian regulatory guidelines harmonised with the international norms and regulations.

  • Open Access

    Comparative Analysis of Approaches to Assess the Quality of Inactivated Influenza Vaccines: Regulatory Requirements in the Russian Federation and European Union

    by L. M. Khantimirova, S. G. Guseva, V. A. Shevtsov, V. A. Merkulov, V. P. Bondarev

    The experience with the influenza pandemic caused by strain A (H1N1) 2009 and the existing gaps in standardizing and evaluating the quality and effectiveness of vaccines for influenza prevention have led the European Union (EU) to recognize the need to review / update the current guidelines on requirements for the development, quality, and preclinical and clinical research. In February 2018 Guideline on influenza vaccines -quality module (EMA/CHMP/BWP/310834/2012 Rev.l) came Into effect In the EU countries. The formation of the Eurasian Economic Union (EAEU) and the creation of a single market for pharmaceutical products entails the need to amend the current and the formation of new legislation, as well as changes in the rules and regulations regarding the pharmaceutical circulation processes in the Russian Federation: development, quality assurance in preclinical and clinical trials, monitoring the safety of medicines for medical use, in this regard, it seems appropriate to develop scientific and technical guidelines that are harmonized with international standards and approaches in the pharmaceutical field. The aim of the review was to conduct a comparative analysis of approaches to assessing the quality of vaccines for prevention influenza based regulatory requirements in the Russian Federation and European Union. Conclusion. In this article discusses the features of the requirements for the development and quality control of inactivated influenza vaccines in the Russian Federation and the EU. The article provides a comparative analysis of the requirements of the State Pharmacopoeia of the Russian Federation and the European Pharmacopoeia for quality indicators, which should be included in the regulatory documentation when registering the vaccine. The main changes in the EMA document «Guidelines for influenza vaccines - Quality module» consist of new approaches to standardizing vaccines for influenza prevention, in particular, determining the specific activity of inactivated influenza vaccines using adequate alternative methods and studying biological, immunological and physicochemical characteristics HA antigen using a wide range method. The results of the analysis of approaches to assessing the quality of vaccines for influenza prevention can be useful in developing harmonized with international norms and approaches scientific and technical guidelines in the pharmaceutical field.


  • Open Access

    An Outbreak of a New Infectious Disease COVID-19: β-coronaviruses as a Threat to Global Healthcare

    by D. V. Gorenkov, L. M. Khantimirova, V. A. Shevtsov, A. V. Rukavishnikov, V. A. Merkulov, Yu. V. Olefir

    Coronaviruses are the largest group of known positive-strand RNA viruses. Coronavirus infection can affect various animal species, as well as humans. Over the past two decades, coronaviruses have caused epidemic outbreaks of two respiratory diseases: the Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome. At the end of 2019, a new type of virus was detected in China. The virus has been spread by humantohuman transmission and has caused a viral pneumonia outbreak. The emergence of a new coronavirus proves that the diseases caused by this group of viruses pose a threat to global health due to the potential for a pandemic, and, therefore, need careful monitoring. The objective of the study was to analyse the current epidemic situation for the new coronavirus infection (COVID-19) caused by SARS-CoV-2, taking into account previous outbreaks of infections caused by MERS-CoV and SARS-CoV β-coronaviruses which pose the greatest threat to human health. The review briefly describes two epidemic outbreaks caused by SARS-CoV (2002–2004) and MERS-CoV (2012–present), summarises the current epidemic situation for the new SARS-CoV-2 coronavirus, describes the main restrictive measures undertaken to prevent the spread of infection in Russia. The paper considers aspects of potential specific therapy and the development of prophylactic vaccines against the new coronavirus infection. The review concludes that SARS-CoV-2 has pandemic potential and that new strains of β-coronaviruses are likely to cause outbreaks in the future. The paper points to the need for careful monitoring of the disease and conducting preventive anti-epidemic measures to curb the spread of infection.


  • Open Access

    Vaccine Safety and Efficacy in Preventing Rotavirus Infection

    by V. A. Shevtsov, E. E. Evreinova, I. N. Indikova, L. M. Khantimirova, D. V. Gorenkov, A. V. Rukavishnikov

    The rotavirus infection causes acute gastroenteritis and is a major cause of lethal severe dehydrating diarrhoea in children under 5 years of age worldwide. Live attenuated rotavirus vaccines are the only means of preventing severe forms of the disease. The aim of the study was to analyse the twenty-year international experience of prophylactic immunisation against rotavirus infection. The paper summarises safety and efficacy data on the long-term use of Rotarix® (Belgium) and RotaTeq® (USA) for the prevention of rotavirus infection in the WHO European Region, the European Union and other countries. It addresses the development of correlates of immune protection for vaccines as well as evaluation of efficacy and safety of the new vaccines Rotavac® and Rotasiil® (India) in clinical trials. The authors analysed international experience of using the vaccines in countries that do not keep records of infant mortality from diarrhoea. The study summarises the results of clinical studies on the use of new vaccines prequalified by WHO in 2018 in regions with high rates of infant mortality from diarrhoea. It was demonstrated that vaccination not only reduces the rates of hospital admission of immunised children, but also contributes to the development of herd immunity. Rotarix® and RotaTeq® vaccines are authorised or included in the national immunisation schedules of many countries, but this type of vaccination is not mandatory in most of these countries. Vaccination coverage in the EU countries is about 24 %. Alternative vaccination schemes using live attenuated vaccines based on strains derived from newborn children, and parenteral rotavirus vaccines which do not replicate in the intestine may help reduce existing risks. It was concluded that the introduction of live rotavirus vaccines in immunisation schedules should be accompanied by the analysis of incidence of intussusception of the small intestine before and after the introduction of mass immunisation, and by active pharmacovigilance.


  • Open Access

    Post-approval Variations to Dossiers for Vaccines: Analysis of Regulatory and Methodological Approaches Used in the Russian Federation and Abroad

    by V. A. Shevtsov, Yu. V. Olefir, V. A. Merkulov, V. P. Bondarev, I. N. Indikova, E. E. Evreinova, A. V. Rukavishnikov, L. M. Khantimirova, D. V. Gorenkov

    Внесение изменений в документы регистрационных досье на вакцины: анализ нормативно-методических подходов в Российской Федерации и за рубежом


  • Open Access

    Retrospective Analysis of Viral Hepatitis B Incidence in Russia from 2013 to 2017 in the Context of Preventive Vaccination

    by L. M. Khantimirova, T. Yu. Kozlova, E. L. Postnova, V. A. Shevtsov, A. V. Rukavishnikov

    The article presents the results of a retrospective analysis of viral hepatitis B incidence in the Russian Federation from 2013 to 2017, taking into account the use of vaccines included into the National Immunisation Schedule and the Immunisation Programme in Case of Epidemic Outbreaks. The analysis of the data revealed a trend towards a reduction in the incidence of acute and chronic forms of hepatitis B in the territory of the Russian Federation during the past five years. The reduction of viral hepatitis B incidence was achieved thanks to a higher vaccination coverage of both children and adults. The article presents an overview of monovalent and combination recombinant hepatitis B vaccines licensed in the Russian Federation. It describes the WHO position on preventive vaccination against viral hepatitis B, and pays special attention to vaccination of people at risk. The article considers promising areas for improving immunobiological products for hepatitis B prevention, including new technologies used in vaccine production, development and introduction of new adjuvants or adjuvants systems, and development of therapeutic vaccines.


  • Open Access

    Analysis of Efficacy and Safety of Tick-Borne Encephalitis Vaccines

    by T. Yu. Kozlova, L. M. Khantimirova, A. V. Rukavishnikov, V. A. Shevtsov

    В статье приведен анализ эффективности и безопасности вакцин для профилактики клещевого энцефалита (КЭ), разрешенных для применения на территории Российской Федерации. Показано, что используемые в настоящее время вакцины КЭ отечественного и зарубежного производства обеспечивают высокую иммуногенность, безопасность и эпидемиологическую эффективность в регионах с массовым охватом вакцинацией. Все зарегистрированные вакцины соответствуют основным принципам взаимозаменяемости по показаниям к применению с учетом возрастных ограничений, перечню медицинских противопоказаний, схемам вакцинации, составу вакцин, а также показателям безопасности, иммунологической активности и эффективности. Своевременные меры специфической профилактики приводят к снижению заболеваемости КЭ в эндемичных регионах.